272 related articles for article (PubMed ID: 9021203)
21. Comparative pharmacokinetic and pharmacodynamic profile of piperacillin/tazobactam 3.375G Q4H and 4.5G Q6H.
Mattoes HM; Capitano B; Kim MK; Xuan D; Quintiliani R; Nightingale CH; Nicolau DP
Chemotherapy; 2002 May; 48(2):59-63. PubMed ID: 12011536
[TBL] [Abstract][Full Text] [Related]
22. Comparison of the pharmacodynamic activity of cefotaxime plus metronidazole with cefoxitin and ampicillin plus sulbactam.
Sullivan MC; Nightingale CH; Quintiliani R; Sweeney KR
Pharmacotherapy; 1995; 15(4):479-86. PubMed ID: 7479201
[TBL] [Abstract][Full Text] [Related]
23. Clavulanate induces expression of the Pseudomonas aeruginosa AmpC cephalosporinase at physiologically relevant concentrations and antagonizes the antibacterial activity of ticarcillin.
Lister PD; Gardner VM; Sanders CC
Antimicrob Agents Chemother; 1999 Apr; 43(4):882-9. PubMed ID: 10103195
[TBL] [Abstract][Full Text] [Related]
24. Effect of bovine lactoferrin on the MICs of ampicillin/sulbactam (UNASYN), amoxicillin/clavulanic acid (Augmentin), ticarcillin clavulanate (Timentin), and piperacillin-tazobactam (ZOSYN), against clinical and environmental isolates of motile Aeromonas.
WaKabongo M; Stucki ZN; Torbert DP; Olweny J
J Am Osteopath Assoc; 2005 Jan; 105(1):25-6. PubMed ID: 15710671
[No Abstract] [Full Text] [Related]
25. Tazobactam is a potent inactivator of selected inhibitor-resistant class A beta-lactamases.
Bonomo RA; Rudin SA; Shlaes DM
FEMS Microbiol Lett; 1997 Mar; 148(1):59-62. PubMed ID: 9066111
[TBL] [Abstract][Full Text] [Related]
26. Piperacillin/tazobactam (YTR 830) combination. Comparative antimicrobial activity against 5889 recent aerobic clinical isolates and 60 Bacteroides fragilis group strains.
Jones RN; Pfaller MA; Fuchs PC; Aldridge K; Allen SD; Gerlach EH
Diagn Microbiol Infect Dis; 1989; 12(6):489-94. PubMed ID: 2560421
[TBL] [Abstract][Full Text] [Related]
27. In-vitro susceptibilities of species of the Bacteroides fragilis group to newer beta-lactam agents.
Betriu C; Sánchez A; Gómez M; Palau ML; Picazo JJ
J Antimicrob Chemother; 1999 Jan; 43(1):133-6. PubMed ID: 10381111
[TBL] [Abstract][Full Text] [Related]
28. In vitro activities of the beta-lactamase inhibitors clavulanic acid, sulbactam, and tazobactam alone or in combination with beta-lactams against epidemiologically characterized multidrug-resistant Acinetobacter baumannii strains.
Higgins PG; Wisplinghoff H; Stefanik D; Seifert H
Antimicrob Agents Chemother; 2004 May; 48(5):1586-92. PubMed ID: 15105109
[TBL] [Abstract][Full Text] [Related]
29. In vitro activities of beta-lactam-beta-lactamase inhibitor combinations against Stenotrophomonas maltophilia: correlation between methods for testing inhibitory activity, time-kill curves, and bactericidal activity.
Muñoz Bellido JL; Muñoz Criado S; García García I; Alonso Manzanares MA; Gutiérrez Zufiaurre MN; García-Rodríguez JA
Antimicrob Agents Chemother; 1997 Dec; 41(12):2612-5. PubMed ID: 9420028
[TBL] [Abstract][Full Text] [Related]
30. Activity of ticarcillin/clavulanate and piperacillin/tazobactam (YTR 830; CL-298,741) against clinical isolates and against mutants derepressed for class I beta-lactamase.
Knapp CC; Sierra-Madero J; Washington JA
Diagn Microbiol Infect Dis; 1989; 12(6):511-5. PubMed ID: 2560423
[TBL] [Abstract][Full Text] [Related]
31. Interactions of tazobactam and clavulanate with inducibly- and constitutively-expressed Class I beta-lactamases.
Akova M; Yang Y; Livermore DM
J Antimicrob Chemother; 1990 Feb; 25(2):199-208. PubMed ID: 2158496
[TBL] [Abstract][Full Text] [Related]
32. Bactericidal activity of ertapenem against major intra-abdominal pathogens.
Borbone S; Cascone C; Santagati M; Mezzatesta ML; Stefani S
Int J Antimicrob Agents; 2006 Nov; 28(5):396-401. PubMed ID: 17045463
[TBL] [Abstract][Full Text] [Related]
33. Comparative in vitro activity of beta-lactam/beta-lactamase inhibitor combinations against gram negative bacteria.
Mohanty S; Singhal R; Sood S; Dhawan B; Das BK; Kapil A
Indian J Med Res; 2005 Nov; 122(5):425-8. PubMed ID: 16456257
[TBL] [Abstract][Full Text] [Related]
34. Comparison of the bactericidal activities of ofloxacin and ciprofloxacin alone and in combination with ceftazidime and piperacillin against clinical strains of Pseudomonas aeruginosa.
Klepser ME; Patel KB; Nicolau DP; Quintiliani R; Nightingale CH
Antimicrob Agents Chemother; 1995 Nov; 39(11):2503-10. PubMed ID: 8585734
[TBL] [Abstract][Full Text] [Related]
35. Beta-lactamase production in members of the family Enterobacteriaceae and resistance to beta-lactam-enzyme inhibitor combinations.
Thomson KS; Weber DA; Sanders CC; Sanders WE
Antimicrob Agents Chemother; 1990 Apr; 34(4):622-7. PubMed ID: 2344169
[TBL] [Abstract][Full Text] [Related]
36. Cross-resistance to beta-lactam-beta-lactamase inhibitor combinations and clindamycin among cefoxitin-resistant and cefoxitin-susceptible strains of the Bacteroides fragilis group.
Aldridge KE
Diagn Microbiol Infect Dis; 1993 Oct; 17(3):251-6. PubMed ID: 8112038
[TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetic and pharmacodynamic evaluation of two dosing regimens for piperacillin-tazobactam.
Kim MK; Capitano B; Mattoes HM; Xuan D; Quintiliani R; Nightingale CH; Nicolau DP
Pharmacotherapy; 2002 May; 22(5):569-77. PubMed ID: 12013355
[TBL] [Abstract][Full Text] [Related]
38. Comparative activities of the beta-lactamase inhibitors YTR 830, clavulanate, and sulbactam combined with ampicillin and broad-spectrum penicillins against defined beta-lactamase-producing aerobic gram-negative bacilli.
Jacobs MR; Aronoff SC; Johenning S; Shlaes DM; Yamabe S
Antimicrob Agents Chemother; 1986 Jun; 29(6):980-5. PubMed ID: 3015017
[TBL] [Abstract][Full Text] [Related]
39. Importance of beta-lactamase inhibitor pharmacokinetics in the pharmacodynamics of inhibitor-drug combinations: studies with piperacillin-tazobactam and piperacillin-sulbactam.
Lister PD; Prevan AM; Sanders CC
Antimicrob Agents Chemother; 1997 Apr; 41(4):721-7. PubMed ID: 9087477
[TBL] [Abstract][Full Text] [Related]
40. Piperacillin/tazobactam compared with ticarcillin/clavulanate in community-acquired bacterial lower respiratory tract infection.
Shlaes DM; Baughman R; Boylen CT; Chan JC; Charan NB; Cormier YC; Erickson A; Grossman R; Kirmani N; Suh B
J Antimicrob Chemother; 1994 Oct; 34(4):565-77. PubMed ID: 7868408
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
